01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

#EGT European Green Transition PLC – Investor Webinar April 28, 2026 – Posted in: European Green Transition Plc (EGT)

28 April 2026 – European Green Transition plc (AIM: EGT), a company operating in the critical infrastructure sector, announce that Executive Chair, Cathal Friel and CFO, Jack Kelly will be presenting an investor webinar at 6:00pm BST on 7 May 2026. The webinar is open to shareholders and other interested parties and will be hosted by Turner Pope Investments. There will be a Q&A session for investors after the Company’s presentation, for which questions can…

Continue reading

#HVO hVIVO PLC – Presentation at Jefferies Healthcare Conference November 3, 2025 – Posted in: hVIVO (HVO)

hVIVO plc (AIM: HVO), a full-service early phase Contract Research Organisation (CRO) and the world leader in human challenge clinical trials, announces that Yamin ‘Mo’ Khan, Chief Executive Officer, will be presenting in-person at the Jefferies Global Healthcare Conference in London on 20 November 2025 at 12.30pm GMT. Alongside the presentation, the Company will also be available for one-to-one meetings. The Jefferies Global Healthcare Conference is the largest healthcare-dedicated conference in Europe and is taking place between…

Continue reading

#POLB Poolbeg Pharma PLC – H.C. Wainwright Global Investment Conference August 27, 2024 – Posted in: Poolbeg Pharma (POLB)

27 August 2024 - Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that Jeremy Skillington, PhD, Chief Executive Officer and David Allmond, Chief Business Officer will present virtually at the H.C. Wainwright 26th Annual Global Investment Conference, being held on 9-11 September 2024 in New York and virtually. The presentation will be available to view…

Continue reading

#HVO hVIVO – Notice of Results August 24, 2023 – Posted in: hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it will release its interim results for the six months ended 30 June 2023 on Tuesday 12 September 2023.   Investor presentation   Yamin ‘Mo’ Khan, Chief Executive Officer, and Stephen Pinkerton, Chief Financial Officer, will provide a live presentation relating to the interim results via the Investor Meet Company platform on…

Continue reading
Open Orphan

#ORPH Open Orphan – Notice of results August 25, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that it will release its interim results for the six months ended 30 June 2022 on 8 September 2022.   Investor presentation   Yamin ‘Mo’ Khan, Chief Executive Officer, and Leo Toole, Chief Financial Officer, will provide a live presentation relating to the interim results via…

Continue reading
Open Orphan

Open Orphan #ORPH – Presentation at World Vaccine Congress April 12, 2022 – Posted in: Open Orphan (ORPH)

  Presentation at World Vaccine Congress  hVIVO presents on the outcomes from the world’s first COVID-19 characterisation study Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that Dr Andrew Catchpole, Chief Scientific Officer of hVIVO, a subsidiary of Open Orphan plc, will be delivering a presentation at the World Vaccine Congress, Washington D.C., United States, titled ‘Outcome of…

Continue reading